05/15/2024 5:01 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/14/2024 5:07 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/07/2024 5:03 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
04/15/2024 5:02 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
04/15/2024 5:00 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
04/10/2024 5:51 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
04/04/2024 7:03 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 20-F Registration statement / Annual report / Transition report | |
|
03/21/2024 8:20 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
03/21/2024 5:01 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
03/19/2024 5:33 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
03/14/2024 6:00 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
03/06/2024 5:00 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
03/06/2024 5:00 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
02/21/2024 5:00 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
02/06/2024 4:00 PM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 424B5 | |
02/06/2024 4:05 PM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
01/16/2024 11:15 PM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form EFFECT | |
01/12/2024 5:00 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
01/05/2024 5:09 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
01/04/2024 5:00 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
01/04/2024 5:01 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
12/20/2023 3:45 PM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form F-3 Registration statement for securities of certain foreign private issuers | |
12/20/2023 3:30 PM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
12/19/2023 5:00 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
12/18/2023 10:40 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
12/11/2023 5:00 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
12/11/2023 5:01 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
11/27/2023 5:00 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
11/14/2023 5:00 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
11/07/2023 5:01 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
11/03/2023 5:00 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/27/2023 5:01 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/19/2023 5:00 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/16/2023 5:00 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/10/2023 5:00 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/05/2023 5:00 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
09/22/2023 5:00 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
09/14/2023 5:27 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
09/14/2023 5:00 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
08/29/2023 5:00 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
08/10/2023 5:00 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
Elon to Transform U.S. Economy? (Ad) A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites.
And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth. One company holds a near-total monopoly on it. |
07/11/2023 5:00 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/07/2023 5:01 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/26/2023 5:00 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/16/2023 5:00 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/12/2023 5:00 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/12/2023 5:01 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/08/2023 5:00 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/07/2023 5:00 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/26/2023 5:00 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/23/2023 5:00 AM | Innate Pharma (Filer) Innate Pharma SA (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |